Nuformix plc (LON:NFX – Get Free Report) shares dropped 9% on Friday . The company traded as low as GBX 0.18 and last traded at GBX 0.18. Approximately 29,601,219 shares changed hands during trading, a decline of 31% from the average daily volume of 42,834,563 shares. The stock had previously closed at GBX 0.20.
Nuformix Stock Performance
The stock’s fifty day simple moving average is GBX 0.22 and its two-hundred day simple moving average is GBX 0.26. The stock has a market capitalization of £5.14 million, a P/E ratio of -5.01 and a beta of 1.41.
Nuformix (LON:NFX – Get Free Report) last posted its quarterly earnings data on Tuesday, January 27th. The company reported GBX (0.04) earnings per share for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Read More
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
